Non-exclusive Drug Discount Agreement for Flecainide
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Flecainid (ATC-Code nach WHO: C01BC04)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum volume commitment; actual demand depends on physician prescribing and patient needs. Revenue cannot be predi...
The buyer may terminate the Open House if exclusive agreements are concluded, which typically occurs 8-12 months after...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Supply of pharmaceutical products containing Flecainide (ATC C01BC04) under a non-exclusive discount agreement.
- No minimum purchase quantities guaranteed.
Show full summary
This notice announces a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance Flecainide (ATC C01BC04), conducted as an Open House model. The contract is with AOK PLUS for the regions Saxony and Thuringia. There is no guaranteed volume, no exclusivity, and no individual negotiations. The agreement runs until 31 January 2028. Participation is open to all interested pharmaceutical companies that meet the eligibility criteria.
Risks
No minimum volume commitment; actual demand depends on physician prescribing and patient needs. Revenue cannot be predi...
The buyer may terminate the Open House if exclusive agreements are concluded, which typically occurs 8-12 months after...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participants must be pharmaceutical companies within the meaning of § 4 Abs. 18 AMG for the offered medicinal products.
- The company must have its registered office within the scope of the AMG, EU member state, or EEA.
Eligibility
- Declaration of no exclusion grounds under §§ 123, 124 GWB (using provided form).
Requirements may be incomplete.
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Flecainide
Non-exclusive discount agreement for pharmaceutical products containing the active substance Flecainide. Open House model with no exclusivity or guaranteed volumes. Agreement ends 31 January 2028.
Location
Duration
Category
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Flecainid (ATC-Code nach WHO: C01BC04)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 07 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 660388-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum volume commitment; actual demand depends on physician prescribing and patient needs. Revenue cannot be predi...
The buyer may terminate the Open House if exclusive agreements are concluded, which typically occurs 8-12 months after...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications